Share on StockTwits

Mallinckrodt PLC (NYSE:MNK) saw some unusual options trading activity on Tuesday. Investors purchased 9,673 call options on the stock, AmericanBankingNews.com reports. This represents an increase of approximately 1,729% compared to the typical daily volume of 529 call options.

Several analysts have recently commented on the stock. Analysts at BMO Capital Markets upgraded shares of Mallinckrodt PLC from a “market perform” rating to an “outperform” rating in a research note on Tuesday. They now have a $71.00 price target on the stock, up previously from $70.00. Separately, analysts at Leerink Swann raised their price target on shares of Mallinckrodt PLC from $64.00 to $68.00 in a research note on Tuesday. Three analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $59.13.

Shares of Mallinckrodt PLC (NYSE:MNK) traded up 5.38% on Tuesday, hitting $64.23. The stock had a trading volume of 9,132,985 shares. Mallinckrodt PLC has a 52-week low of $41.00 and a 52-week high of $72.93. The stock’s 50-day moving average is $67.42 and its 200-day moving average is $54.81. The company has a market cap of $3.748 billion and a price-to-earnings ratio of 41.52.

Mallinckrodt PLC (NYSE:MNK) last released its earnings data on Thursday, February 6th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.22. The company had revenue of $540.20 million for the quarter, compared to the consensus estimate of $539.24 million. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. Analysts expect that Mallinckrodt PLC will post $2.94 EPS for the current fiscal year.

Mallinckrodt public limited company (NYSE:MNK) is a global specialty pharmaceuticals company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.